Analysts Set ADC Therapeutics SA (NYSE:ADCT) Price Target at $10.17

Shares of ADC Therapeutics SA (NYSE:ADCT – Get Rating) have been given an average recommendation of “Moderate Buy” by the six research firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $10.17.

A number of research firms have recently weighed in on ADCT. Royal Bank of Canada reduced their target price on shares of ADC Therapeutics from $18.00 to $12.00 and set an “outperform” rating on the stock in a report on Monday, February 13th. Morgan Stanley reduced their target price on shares of ADC Therapeutics from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Tuesday, January 24th. Capital One Financial began coverage on shares of ADC Therapeutics in a report on Tuesday, December 6th. They issued an “overweight” rating and a $12.00 target price on the stock. Finally, HC Wainwright reduced their target price on shares of ADC Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, January 4th.

ADC Therapeutics Stock Down 2.6 %

Shares of NYSE ADCT opened at $2.24 on Thursday. The company has a current ratio of 4.51, a quick ratio of 4.32 and a debt-to-equity ratio of 1.10. The firm’s fifty day moving average is $4.08 and its two-hundred day moving average is $4.27. ADC Therapeutics has a 52-week low of $2.15 and a 52-week high of $16.04.

Hedge Funds Weigh In On ADC Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC boosted its position in ADC Therapeutics by 12.5% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 21,933 shares of the company’s stock valued at $84,000 after buying an additional 2,431 shares during the period. Advisor Group Holdings Inc. boosted its position in ADC Therapeutics by 1,270.5% in the 1st quarter. Advisor Group Holdings Inc. now owns 3,248 shares of the company’s stock valued at $47,000 after buying an additional 3,011 shares during the period. Quantbot Technologies LP purchased a new stake in ADC Therapeutics in the 2nd quarter valued at about $38,000. Hennion & Walsh Asset Management Inc. boosted its position in ADC Therapeutics by 14.2% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 58,869 shares of the company’s stock valued at $226,000 after buying an additional 7,337 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in ADC Therapeutics by 1,253.3% in the 3rd quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock valued at $46,000 after buying an additional 8,773 shares during the period. 75.56% of the stock is currently owned by institutional investors.

ADC Therapeutics Company Profile

(Get Rating)

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL).